Junctional Epidermolysis Bullosa Inversa C2673609
A severe inherited skin blistering disorder where the skin forms fragile blisters, often in body folds and flexural areas. Care focuses on wound management and preventing complications.
Key facts at a glance
- ICD-10
- Q84.9
- ICD-11
- LA00.0
- Body system
- dermatologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(dermatologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Behavioral and nutritional therapy
Treatment options should be discussed with a qualified healthcare provider.
Wound Care Management
Gentle wound care with non-adherent dressings, silicone-based products, and careful blister management to prevent secondary infections and promote healing.
Topical Antibiotic Therapy
Application of topical antibiotics such as mupirocin or fusidic acid to infected wounds to prevent bacterial overgrowth and complications.
When to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Junctional Epidermolysis Bullosa Inversa C2673609?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Fine JD, Bruckner-Tuderman L, Eady RA, et al. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J Am Acad Dermatol. 2014;70(6):1103-1126.
Mellerio JE, Bolling M, Brahmadathan KN, et al.Genodermatosis Working Groups. Gene therapies for epidermolysis bullosa: a review of clinical trials. Br J Dermatol. 2022;187(3):321-334.
Has C, Liu L, Bolling MC, et al. Clinical practice guidelines for laboratory diagnosis of epidermolysis bullosa. Br J Dermatol. 2020;182(3):574-592.
Puckett Y, Bhargava S, Rodriguez Cannici G, Bhimarasetty R. Junctional Epidermolysis Bullosa. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023.
Medication Comparisons
Compare medications used to treat Junctional Epidermolysis Bullosa Inversa C2673609. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy